On 26 August 2024, Insulet Corporation announced that it received FDA approval for its Omnipod® 5 Automated Insulin Delivery (AID) System for use in the US by people with type 2 diabetes (ages 18 years and older).
The Omnipod® 5 is a wearable device which provides up to three days of continuous insulin delivery. It works in concert with a continuous glucose monitor to manage blood glucose and automatically delivers insulin without patient input. It is the first and only AID system cleared by the FDA for both type 1 and type 2 diabetes management.
This news follows other recent advancements in insulin treatments with Novo Nordisk’s weekly injection insulin Icodec nearing approval in India.